Abstract
This study presents the first results of a molecular-genetic study of colorectal cancer (CRC) in Kazakhstan. Blood samples were collected from patients diagnosed with rectal or colon cancer (249 individuals) as well as a control cohort of healthy volunteers (245 individuals), taking into account the age, gender, ethnicity, and smoking habits of the CRC patients. Combined analysis of data obtained from individuals of either Kazakh or Russian decent showed a significant association with increased CRC risk in the following genotypes: DCC (32008376G/G and G/A versus A/A; OR = 3.45, 95 % confidence interval (95 %CI) = 1.75–6.81, χ 2 = 14.07, p < 0.0002), MLH1 (-93G/G versus G/A and A/A; OR = 1.45, 95 %CI = 1.02–2.07, χ 2 = 4.21, p < 0.04), TP53 (Pro72Pro; OR = 3.80, 95 %CI = 2.46–5.88, χ 2 = 61.27, p < 0.0001), combination GSTT1 deletions with heterozygotes versus normal homozygotes (OR = 1.43, 95 %CI = 1.00–2.04, χ 2 = 3.90, p < 0.05), and GSTM1 deletions (OR = 1.83, 95 %CI = 1.28–2.63, χ 2 = 11.04, p < .001). Analysis for ethnicity and smoking for each of the investigated polymorphisms showed that some genotypes can have a predictive value for susceptibility to CRC, at least those that demonstrate statistically significant ORs either for the combined mixed population of Kazakhstan or for both main ethnic groups separately (Kazakhs and Russians): TP53 Pro72Pro homozygous (for Kazakh—OR = 3.40, 95 %CI = 1.63–7.06, χ 2 = 11.35, p < 0.003; for Russian—OR = 4.69, 95 %CI = 2.53–8.66, χ 2 = 53.19, p < 0.0001) and GSTM1 deletions (for Kazakh—OR = 2.30, 95 %CI = 1.21–4.40, χ 2 = 8.42, p < 0.01; for Russian—OR = 1.64, 95 %CI = 1.01–2.66, χ 2 = 7.82, p < 0.02).
Similar content being viewed by others
References
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–502.
Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268–74.
Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;11:1513–30.
Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15:699–731.
Economopoulos KP, Sergentanis TN. GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis. Eur J Cancer. 2010;46:1617–31.
Migliore L, Migheli F, Spisni R, Coppede F. Genetics, cytogenetics, and epygenetics of colorectal cancer. J Biomed Biotech. 2011. doi:10.1155/2011/792362.
Taflin H, Wettergren Y, Odin E, Carlsson G, Derwinger K. Folate levels and polymorphisms in the genes MTHFR, MTR, and TS in colorectal cancer. Clin Med Insights Oncol. 2014;8:15–20. doi:10.4137/CMO.S12701.
Peng Q, Yang S, Lao X, Tang W, Chen Z, Lai H, et al. Meta-analysis of the association between COX-2 polymorphisms and risk of colorectal cancer based on case–control studies. PLoS ONE. 2014. doi:10.1371/journal.pone.0094790.
Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, et al. Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell. 1996;87:175–85.
Akkiprik M, Ataizi-Celikel C, Düúünceli F, Sönmez O, Gulluoglu BM, Sav A, et al. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers. J Gastrointest and Liver Dis. 2007;16:11–7.
Toma M, Stavarachi M, Cimponeriu D, Apostol P, Cojocaru M, Beluşică L, et al. P53 and DCC polymorphisms and the risk for colorectal cancer in Romanian patients—a preliminary study. J Analele Universităţii din Oradea, Fascicula Biol. 2009;16:162–5.
Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, et al. Mutations and polymorphisms in TP53 gene—an overview on the role in colorectal cancer. Mutagenesis. 2012;27:211–8.
Raptis S, Mrkonjic M, Green RC, Pethe VV, Monga N, Chan YM, et al. MLH1–93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst. 2007;99:463–74.
Allan JM, Shorto J, Adlard J, Bury J, Coggins R, George R, et al. MLH1–93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer. 2008;123:2456–9. doi:10.1002/ijc.23770.
Nizam ZM, Abdul Aziz AA, Kaur G, Abu Hassan MR, Mohd Sidek AS, Yeh LY, et al. Contribution of the MLH1–93G>A promoter polymorphism in modulating susceptibility risk in Malaysian colorectal cancer patients. Asian Pac J Cancer Prev. 2013;14:619–24.
Djansugurova LB, Perfilyeva AV, Zhunusova GS, Djantaeva KB, Iksan OA, Khussainova EM. The determination of genetic markers of age-related cancer pathologies in populations from Кazakhstan. Front Genet. 2013. doi:10.3389/fgene.2013.00070.
Abbas A, Delvinquiere K, Lechevrel M, Lebalilly P, Gauduchon P, Launoy G, et al. GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in French population: different pattern of squamous cell carcinoma and adenocarcinoma. World J Gastroenterol. 2004;10:3389–93.
Khan NP, Pandith AA, Hussain MU, Yousuf A, Khan MS, Siddiqi MA, et al. Loss of heterozygosity (LOH) of deleted in colorectal cancer (DCC) gene and predisposition to colorectal cancer: significant association in colorectal cancer patients of Kashmir. J Cancer Res Expt Oncol. 2011;3:88–94.
Rai R, Sharma KL, Tiwari S, Misra S, Kumar A, Mittal B. DCC (deleted in colorectal carcinoma) gene variants confer increased susceptibility to gallbladder cancer. Gene. 2013;518:303–9.
Park SH, Lee GY, Jeon HS, Lee SJ, Kim KM, Jang SS, et al. 93G>A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer. 2004;112:678–82.
Lu XM, Zhang YM, Lin RY, Liang XH, Wang X, Zhang Y, et al. p53 polymorphism in human papillomavirus-associated Kazakh’s esophageal cancer in Xinjiang, China. World J Gastroenterol. 2004;10:2775–8.
D’Errico A, Malats N, Vineis P, Boffetta P. Review of studies of selected metabolic polymorphisms and cancer. IARC Sci Publ. 1999;148:323–93.
Ketterer B, Taylor J, Meyer D, Pemble S, Coles B, ChuLin X, et al. Structure and functions of glutathione S-transferases. CRC Press Boca Raton Florida. 2007;15:15–27.
Gao LB, Pan XM, Li LJ, Liang WB, Bai P, Rao L, et al. Null genotypes of GSTM1 and GSTT1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis. PLoS ONE. 2011;6:1–7. doi:10.1371/journal.pone.0020157.
Malik MA, Gupta A, Zargar SA, Mittal B. Role of genetic variants of deleted in colorectal carcinoma (DCC) polymorphisms and esophageal and gastric cancers risk in Kashmir Valley and meta-analysis. Tumor Biol. 2013;34:3049–57. doi:10.1007/s13277-013-0870-4.
Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case–control studies. Int J Cancer. 2010;129:920–30.
Dumont P, Leu JI, Della Pietra 3rd AC, George DL, Murphy M. The codon 72 polymorphic variants of TP53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.
Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, et al. Polymorphism in wild-type TP53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23:3328–37.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–34.
Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, et al. TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep. 2011;388:4847–53. doi:10.1007/s11033-010-0619-8.
Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer. 2006;118:1790–7.
Perfumo C, Bonelli L, Menichini P, Inga A, Gismondi V, Ciferri E, et al. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion. 2006;74:228–35.
Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, et al. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol. 2007;37:385–90.
Dastjerdi MN, Salehi M, Mohajeri MR. Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan. J of Res in Med Sci. 2008;13:317–23.
Cao Z, Song JH, Park YK, Maeng EJ, Nam SW, Lee JY, et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma. 2009;56:114–8.
Sameer AS, Shah ZA, Syeed N, Banday MZ, Bashir SM, Bhat BA, et al. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res. 2010;9:651–60.
Rajagopal R, Deakin M, Fawole AS, Elder JB, Elder J, Smith V, et al. Glutathione S-transferase T1 polymorphisms are associated with outcome in colorectal cancer. Carcinogenesis. 2005;26:2157–63. doi:10.1093/carcin/bgi195.
Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, et al. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res. 2008;28:1917–22.
Katoh T, Nagata N, Kuroda Y, Itoh H, Kawahara A, Kuroki N, et al. Glutathione S-transferase Ml (GSTM1) and Tl (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis. 1996;17:1855–9.
Moore LE, Huang WY, Chatterjee N, Gunter M, Chanock S, Yeager M, et al. GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2005;14:1823–7.
Huang K, Sandler RS, Millikan RC, Schroeder JC, North KE, Hu J. GSTM1 and GSTT1 polymorphisms, cigarette smoking, and risk of colon cancer: a population-based case–control study in North Carolina (United States). Cancer Causes Control. 2006;17:385–94.
Gertig DM, Stampfer M, Haiman C, Hennekens CH, Kelsey K, Hunter DJ. Glutathione S-transferase GSTM1 and GSTT1 polymorphisms and colorectal cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 1998;7:1001–5.
Little J, Sharp L, Masson LF, Brockton NT, Cotton SC, Haites NE, et al. Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: a case–control study in the Grampian region of Scotland. Int J Cancer. 2006;119:2155–64.
Ye Z, Parry JM. A meta-analysis of 20 case–control studies of the glutathione S-transferase M1 (GSTM1) status and colorectal cancer risk. Med Sci Monit. 2003;9:SR83–91.
Pan XM, Yang WZ, Xu GH, Bai P, Qin HJ, Zhang LS, et al. The association between MLH1–93G>A polymorphism of DNA mismatch repair and cancer susceptibility: a meta-analysis. Mutagenesis. 2011;26:667–73. doi:10.1093/mutage/ger032.
Perera S, Mrkonjic M, Rawson JB, Bapat B. Functional effects of the MLH1–93G>A polymorphism on MLH1/EPM2AIP1 promoter activity. Oncol Rep. 2011;25:809–15.
Chen H, Taylor NP, Sotamaa KM, Mutch DG, Powell MA, Schmidt AP, et al. Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer. 2007;120:1684–8.
Koessler T, Oestergaard MZ, Song H, Tyrer J, Perkins B, Dunning AM, et al. Common variants in mismatch repair genes and risk of colorectal cancer. Gut. 2008;57:1097–101.
Campbell PT, Curtin K, Ulrich CM, Samowitz WS, Bigler J, Velicer CM, et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut. 2009;58:661–7.
Muniz-Mendoza R, Ayala-Madrigal ML, Partida-Pérez M, Peregrina-Sandoval J, Leal-Ugarte E, Macías-Gómez N, et al. MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer. Genet Mol Res. 2012;11:2315–20. doi:10.4238/2012.June.27.6.
Jha R, Gaur P, Sharma SC, Das SN. Single nucleotide polymorphism in hMLH1 promoter and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Gene. 2013;526:223–7.
Lee KM, Choi JY, Kang C, Kang CP, Park SK, Cho H, et al. Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res. 2005;11:4620–6.
Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990;247:49–56.
Fearon ER. DCC: is there a connection between tumorigenesis and cell guidance molecules? Biochim Biophys Acta. 1996;9:17–23.
Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele Jr G, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med. 1996;335:1727–32.
Sun XF, Rütten S, Zhang H, Nordenskjöld B. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol. 1999;17:1745–50.
Zhang H, Arbman G, Sun XF. Codon 201 polymorphism of DCC gene is a prognostic factor in patients with colorectal cancer. Cancer Detect Prev. 2003;27:216–21.
Starinsky S, Figer A, Ben-Asher E, Geva R, Flex D, Fidder HH, et al. Genotype phenotype correlations in Israeli colorectal cancer patients. Int J Cancer. 2005;114:58–73.
Cha PC, Zembutsu H, Takahashi A, Kubo M, Kamatani N, Nakamura YJ. A genome-wide association study identifies SNP in DCC is associated with gallbladder cancer in the Japanese population. Hum Genet. 2012;57:235–7.
Acknowledgments
This work was supported by grant N.0067/GF of the Committee of Science, Ministry of Education and Science of Republic of Kazakhstan. MIP was funded by grants from the ICGEB, the Medical Research Council, and the University of Cape Town.
We would like to express our gratitude to the doctors of Almaty Oncology Centre for the help in collecting biosamples and histological testing. Very special thanks are expressed to the rector of the Asfendiyarov Kazakh National Medical University Aikan Akanov and Head of Oncological Department Bakhyt Kh. Khaidarov who managed the research and did ethical attestation.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 52 kb)
Rights and permissions
About this article
Cite this article
Djansugurova, L., Zhunussova, G., Khussainova, E. et al. Association of DCC, MLH1, GSTT1, GSTM1, and TP53 gene polymorphisms with colorectal cancer in Kazakhstan. Tumor Biol. 36, 279–289 (2015). https://doi.org/10.1007/s13277-014-2641-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-2641-2